arrow
H

Hiroyuki Kishi

University of Toyama
H指数:40
被引数:6,684

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

IL-8 blockade enhances anti-PD-1 therapeutic activity in renal cell carcinoma in a next-generation patient-derived xenograft model

IL-8阻断增强下一代患者源性异种移植模型中肾细胞癌的抗PD-1治疗活性

2026-06-010
OAAI
Position-5-driven reorientation of an immunodominant HLA-A*24:02 SARS-CoV-2 epitope drives universal T cell escape

位置5驱动的免疫优势HLA-A*24:02 SARS-CoV-2表位重取向驱动通用T细胞逃逸

2026-05-080
OA
N-terminal pyroglutamylation of an HLA-A24-restricted immunodominant epitope enhances SARS-CoV-2-specific T-cell responses

HLA-A24限制性优势表位的N端焦谷氨酰化增强了SARS-CoV-2特异性T细胞应答

2026-04-270
OAAI
Juzentaihoto modulates gut microbiota and potentiates the anti-tumor effect of anti-PD-1 antibody in an immunogenic mouse melanoma model

救心汤调节肠道微生物群并增强抗PD-1抗体在免疫原性小鼠黑色素瘤模型中的抗肿瘤效果

2026-02-030
PRE
Candidate tumor-specific CD8+ T cell subsets identified in the malignant pleural effusion of advanced lung cancer patients by single-cell analysis
2024-06-282
OA
Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies

CD26-Expressing T细胞恶性肿瘤的新型CD26-Targeted嵌合抗原受体T细胞疗法的开发

CELLS
IF5.2
2023-08-145
OAAI
DPP8 Selective Inhibitor Tominostat as a Novel and Broad-Spectrum Anticancer Agent against Hematological Malignancies

DPP8选择性抑制剂Tominostat作为抗血液系统恶性肿瘤的新型广谱抗癌剂

CELLS
IF5.2
2023-04-063
OAAI
Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants

新型超中和抗体UT28K能够保护免受多种SARS-CoV-2变体的感染

MABS
IF7.3
2022-05-117
OAAI